Decoy Therapeutics Inc. (DCOY)

Price, with every insider trade on it

Closing prices, 12 months · point at a dot for who traded, or at the line for the close

1.47 on 9 Oct 2026

0 buys0 sales at will0 planned sales

Fiscal year 2022, ended 31 Dec 2022, as filed

Revenue

$0.00

Net income

$31.61M

Free cash flow

$17.60M

Return on equity

-304.4%

Return on capital

-242.2%

Fiscal years, as filed with the SEC · point at a year for the detail

RevenueNet incomeLoss

From Form 4, most recent first

Date	Insider	Type	Value	Of own stake
30 Dec 2025	HANISH ARNOLD C Director	Sold at will	$9.60	0.3%
30 Dec 2025	HANISH ARNOLD C Director	Sold at will	$7.68	100%
20 Nov 2025	Rosenblum Mark J Exec VP Finance, CFO	Bought	$16.00K	11,299%
20 Nov 2025	HANISH ARNOLD C Director	Bought	$3.74K	33,333%
7 Jun 2022	Lieber Jonathan I Director	Bought	$7.02K	opened
7 Jun 2022	Burleson Tess Director	Bought	$4.99K	637%

35out of 100

Profitability 25

Financial strength 59

Growth 0

Insiders 62

Strongest on insiders (62), weakest on growth (0). A score of the business, not of the price.

Last 12 months

Only here

Bought

$19.74K

2 buys, 2 buyers

Sold

$17.27

2 sales

Planned sales

under a 10b5-1 plan